de Groot P F, Frissen M N, de Clercq N C, Nieuwdorp M
a Department of Internal and Vascular Medicine , Academic Medical Center , Amsterdam , The Netherlands.
b Wallenberg Laboratory, Department of Molecular and Clinical Medicine , Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden.
Gut Microbes. 2017 May 4;8(3):253-267. doi: 10.1080/19490976.2017.1293224. Epub 2017 Feb 27.
The history of fecal microbiota transplantation (FMT) dates back even to ancient China. Recently, scientific studies have been looking into FMT as a promising treatment of various diseases, while in the process teaching us about the interaction between the human host and its resident microbial communities. Current research focuses mainly on Clostridium difficile infections, however interest is rising in other areas such as inflammatory bowel disease (IBD) and the metabolic syndrome. With regard to the latter, the intestinal microbiota might be causally related to the progression of insulin resistance and diabetes. FMT in metabolic syndrome has proven to be an intriguing method to study the role of the gut microbiota and open the way to new therapies by dissecting in whom insulin resistance is driven by microbiota. In this article we review the history of FMT, the present evidence on its role in the pathophysiology of metabolic syndrome and its efficacy, limitations and future prospects.
粪便微生物群移植（FMT）的历史甚至可以追溯到古代中国。最近，科学研究一直在探索将FMT作为治疗各种疾病的一种有前景的方法，在此过程中也让我们了解了人类宿主与其常驻微生物群落之间的相互作用。目前的研究主要集中在艰难梭菌感染上，不过在其他领域，如炎症性肠病（IBD）和代谢综合征，人们的兴趣也在增加。关于后者，肠道微生物群可能与胰岛素抵抗和糖尿病的进展存在因果关系。代谢综合征中的FMT已被证明是一种研究肠道微生物群作用的有趣方法，通过剖析哪些人的胰岛素抵抗是由微生物群驱动的，为新疗法开辟了道路。在本文中，我们回顾了FMT的历史、其在代谢综合征病理生理学中的作用的现有证据及其疗效、局限性和未来前景。
